Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
202 Results for "
CREB
" in MedChemExpress (MCE) Product Catalog:
Products (202)
202 Results for "CREB" in MCE Product Catalog:
Cat. No.: HY-184011
Research Areas:
SERT-IN-4 is a brain-penetrant and orally active SERT inhibitor and ERβ agonist with human SERT IC50 of 16.92 nM and human ERβ EC50 of 3.66 nM. SERT-IN-4 inhibits SERT-mediated substrate transport, increases hippocampal serotonin levels, modulates p-CREB and BDNF expression.SERT-IN-4 reduces immobility in CUMS mice, improves social interaction and reduces inactivity in CSDS mice.SERT-IN-4 can be used for the research of major depressive disorder .
Cat. No.: HY-E70684
Target:
Research Areas:
CDK5 can be mapped to chromosome 7q36 and its expression is upregulated by the transcription factors Fos and CREB through the MEK/ERK pathway and by δFosB. CDK5 plays a vital role in the central nervous system but has functions in other cell types. CDK5 has recently been implicated in diseases, including the development and progression of cancer and neurodegenerative diseases. CDK5/p25NCK Recombinant Human Active Protein Kinase is an ortholog of CDK5 .
Cat. No.: HY-E70685
Target:
Research Areas:
CDK5 can be mapped to chromosome 7q36 and its expression is upregulated by the transcription factors Fos and CREB through the MEK/ERK pathway and by δFosB. CDK5 plays a vital role in the central nervous system but has functions in other cell types. CDK5 has recently been implicated in diseases, including the development and progression of cancer and neurodegenerative diseases. CDK5/p35NCK Recombinant Human Active Protein Kinase is an ortholog of CDK5 .
Cat. No.: HY-P10927A
Synonyms: BRINP2-related peptide TFA
Research Areas:
Target:
Research Areas:
PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases .
Cat. No.: HY-B0188AS
CAS No.: 1219804-97-3
Synonyms: Org GB 94-d3
Cat. No.: HY-B1719AR
CAS No.: 50-10-2
Target:
Research Areas:
Oxyphenonium bromide Standard is the analytical standard of Oxyphenonium bromide (HY-B1719A). This product is intended for research and analytical applications. Oxyphenonium bromide is an orally effective competitive muscarinic acetylcholine receptor (mAChR) antagonist. Oxyphenonium bromide competitively binds to and blocks mAChR, thereby inhibiting the parasympathetic pathway. By inhibiting CHRM4, Oxyphenonium bromide increases cAMP levels and activates the CREB transcriptional program, thereby promoting erythroid progenitor cell expansion. Oxyphenonium bromide can be used in research on asthma, anemia, and gastric ulcers .
Cat. No.: HY-N0265R
CAS No.: 39524-08-8
Synonyms: Akebia saponin D (Standard)
Cat. No.: HY-W747599
CAS No.: 68652-37-9
Synonyms: Tetrasialoganglioside GQ1b sodium
Research Areas:
Ganglioside GQ1b (Tetrasialoganglioside GQ1b) (bovine) sodium is a central and peripheral nervous system ganglioside and an immunostimulator. Ganglioside GQ1b (bovine) sodium modulates NMDA receptor signaling via ERK1/2, PKA, CREB, NR2A, NR2B, and GSK3β, and increases BDNF expression. Ganglioside GQ1b (bovine) sodium reduces Aβ pathology, tau phosphorylation, and APP levels. Ganglioside GQ1b (bovine) sodium can be used for the research of Alzheimer’s disease .
Cat. No.: HY-189630
Target:
Topoisomerase PKA Epigenetic Reader Domain PI3K Akt mTOR Bcl-2 Family Apoptosis Mitochondrial Metabolism Reactive Oxygen Species (ROS)
Research Areas:
Topoisomerase I-IN-25 is a moderate inhibitor of Topoisomerase I-mediated DNA relaxation. Topoisomerase I-IN-25 inhibits the cAMP-PKA-CREB and PI3K-AKT-mTOR signaling pathways. Topoisomerase I-IN-25 downregulates Bcl-2, upregulates Bax, and induces Apoptosis, G2/M phase arrest, mitochondrial dysfunction, and reactive oxygen species accumulation. Topoisomerase I-IN-25 exhibits anticancer activity against hepatocellular carcinoma. Topoisomerase I-IN-25 can be used for research on hepatocellular carcinoma .
Cat. No.: HY-B0188AR
CAS No.: 21535-47-7
Synonyms: Org GB 94 (Standard)
Cat. No.: HY-B0188S
CAS No.: 81957-76-8
Synonyms: Mianserine-d3
Cat. No.: HY-N0005S
CAS No.: 1246833-26-0
Synonyms: Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6
Cat. No.: HY-N0005S1
Synonyms: Diferuloylmethane-d3; Natural Yellow 3-d3; Turmeric yellow-d3
Cat. No.: HY-P11092
Target:
Research Areas:
Cat. No.: HY-P706260
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ATF4; CAMP-Dependent Transcription Factor ATF-4; Prev. TXREB; Tax-Responsive Enhancer Element B67; CREB-2; CREB2; Cyclic AMP-Dependent Transcription Factor ATF-4; Activating Transcription Factor 4 (Tax-Responsive Enhancer Element B67); TAXREB67; CAMP Response Element-Binding Protein 2; Tax-Responsive Enhancer Element-Binding Protein 67; DNA-Binding Protein TAXREB67; Cyclic AMP-Responsive Element-Binding Protein 2; TaxREB67; Activating Transcription Factor 4; CAMP-Responsive Element-Binding Protein 2
Species:
Human
Source:
E. coli
Cat. No.: HY-103100R
CAS No.: 864741-95-7
Target:
Reference Standards 5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO
Research Areas:
SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a Ki value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.
Cat. No.: HY-P80552
Synonyms: Activating transcription factor 2 antibody;
Activating transcription factor 2 splice variant ATF2 var2 antibody;
ATF 2 antibody;
Atf-2 antibody;
Atf2 antibody;
ATF2 protein antibody;
ATF2_HUMAN antibody;
cAMP Response Element Binding Protein 2 antibody;
cAMP response element binding protein CRE BP1 antibody;
cAMP response element-binding protein CRE-BP1 antibody;
cAMP responsive element binding protein 2, formerly antibody;
cAMP-dependent transcription factor ATF-2 antibody;
cAMP-responsive element-binding protein 2 antibody;
CRE BP1 antibody;
CRE-BP antibody;
CREB 2 antibody;
CREB-2 antibody;
CREB2 antibody;
CREBP1 antibody;
Cyclic AMP dependent transcription factor ATF 2 antibody;
Cyclic AMP-dependent transcription factor ATF-2 antibody;
Cyclic AMP-responsive element-binding protein 2 antibody;
D130078H02Rik antibody;
D18875 antibody;
HB 16 antibody;
HB16 antibody;
Histone acetyltransferase ATF2 antibody;
MGC105211 antibody;
MGC105222 antibody;
MGC111558 antibody;
MGC142504 antibody;
mXBP antibody;
MXBP protein antibody;
Tg(Gzma-Klra1)7Wum antibody;
TREB 7 antibody;
TREB7 antibody
Cat. No.: HY-103322
CAS No.: 1135306-29-4
Target:
Research Areas:
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
Cat. No.: HY-160938
CAS No.: 72782-05-9
Synonyms: β-FNA
Research Areas:
β-Funaltrexamine (β-FNA) is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
